413 related articles for article (PubMed ID: 20185938)
1. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
[TBL] [Abstract][Full Text] [Related]
4. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
5. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
Safran H; Dipetrillo T; Akerman P; Ng T; Evans D; Steinhoff M; Benton D; Purviance J; Goldstein L; Tantravahi U; Kennedy T
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):405-9. PubMed ID: 17097832
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
Satoh T; Omuro Y; Sasaki Y; Hamamoto Y; Boku N; Tamura T; Ohtsu A
Cancer Chemother Pharmacol; 2012 Apr; 69(4):949-55. PubMed ID: 22116464
[TBL] [Abstract][Full Text] [Related]
9. [A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
Murata Y; Matsuura T; Kanoshima K; Kuwabara H; Fuyuki A; Tomeno W; Taniguchi R; Uchiyama T; Kuriyama H; Hata Y
Gan To Kagaku Ryoho; 2013 Jul; 40(7):933-6. PubMed ID: 23863740
[TBL] [Abstract][Full Text] [Related]
10. HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options.
Koltz BR; Hicks DG; Whitney-Miller CL
Biotech Histochem; 2012 Jan; 87(1):40-5. PubMed ID: 21745161
[TBL] [Abstract][Full Text] [Related]
11. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
12. [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].
Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2553-5. PubMed ID: 23235178
[TBL] [Abstract][Full Text] [Related]
13. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
14. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
15. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study.
Sawaki A; Ohashi Y; Omuro Y; Satoh T; Hamamoto Y; Boku N; Miyata Y; Takiuchi H; Yamaguchi K; Sasaki Y; Nishina T; Satoh A; Baba E; Tamura T; Abe T; Hatake K; Ohtsu A
Gastric Cancer; 2012 Jul; 15(3):313-22. PubMed ID: 22179434
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
18. HER2 testing in gastric cancer.
Albarello L; Pecciarini L; Doglioni C
Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
[TBL] [Abstract][Full Text] [Related]
19. [HER2 testing and targeted therapy in advanced gastric cancer].
Höhler T; Rüschoff J; Ridwelski K; Moehler M
Onkologie; 2010; 33 Suppl 4():26-30. PubMed ID: 20431310
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer.
Cosson VF; Ng VW; Lehle M; Lum BL
Cancer Chemother Pharmacol; 2014 Apr; 73(4):737-47. PubMed ID: 24519752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]